{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-044541","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.314171+00:00","generated_at":"2026-05-30T07:21:21.171021+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M","bullets":["Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).","Net income $1.9M ($0.02 EPS) vs net loss $1.0M ($0.01 loss) in Q3 2023.","Record Adjusted EBITDA $2.9M, up from $0.5M YoY; operating cash $32.4M.","Niagen ingredient sales $6.7M (+368% YoY); Tru Niagen sales $18.1M (+4% YoY).","Expanded Niagen+ to >100 wellness clinics; pursuing FDA IND for Ataxia Telangiectasia."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-044541","json":"https://secwatch.observer/filing/0001628280-24-044541.json","markdown":"https://secwatch.observer/filing/0001628280-24-044541.md","text":"https://secwatch.observer/filing/0001628280-24-044541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024044541/0001628280-24-044541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024044541/cdxc-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:21:21.171021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}